SCHEMBL13629411

SCHEMBL13629411

CCc1ccc(NS(=O)(=O)c2ccc(Cl)cc2Cl)cc1F

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 9/20 0.55
ITGA1 P56199 4/20 0.53
LMNA P02545 2/20 0.51
MEN1 O00255 1/20 0.51
MAPT P10636 1/20 0.51
ALOX12 P18054 1/20 0.51
KMT2A Q03164 1/20 0.51
NLRP1 Q9C000 1/20 0.51
CYP3A4 P08684 1/20 0.49
TP53 P04637 1/20 0.49
CDK1 P06493 1/20 0.48
CCNB1 P14635 1/20 0.48
CCNA2 P20248 1/20 0.48
CDK2 P24941 1/20 0.48
CDK7 P50613 1/20 0.48
CCNH P51946 1/20 0.48
CCNA1 P78396 1/20 0.48
HDAC1 Q13547 1/20 0.47
HDAC8 Q9BY41 1/20 0.47
ALDH1A1 P00352 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13629290 0.90 BRD4 (0.52) PPARGITGA1MAPTALDH1A1CCR2
SCHEMBL13629296 0.90 ALDH1A1 (0.57) LMNAMEN1MAPTKMT2ATP53
SCHEMBL13629338 0.85 SLC22A12 (0.53) LMNAMEN1KMT2AHDAC1HDAC8
SCHEMBL13629408 0.85 CDK1 (0.51) PPARGCYP3A4CDK1CCNB1CCNA2
SCHEMBL13629466 0.84 BRPF1 (0.46) PPARGCYP3A4
SCHEMBL13629403 0.82 CES1 (0.58) LMNAMEN1MAPTKMT2ACYP3A4
SCHEMBL13615225 0.82 PPARG (0.55) PPARGITGA1LMNAMEN1MAPT
SCHEMBL13629312 0.81 ALDH1A1 (0.58) LMNAMEN1KMT2AALDH1A1
SCHEMBL13629298 0.80 MEN1 (0.49) LMNAMEN1MAPTKMT2ACYP3A4
SCHEMBL13629418 0.79 PKM (0.61) LMNAMAPTHDAC1HDAC8ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090275593-A1 3 Substituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors NOVARTIS AG 2009-11-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090275593-A1 3 Substituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors TIE1, TEK, MATK PPARG 1808/4885ITGA1 2130/4885LMNA 2608/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.